ANZCTR search results

What the study is about: This study will evaluate whether Enzomenib, a menin inhibitor, can reduce relapse risk when given as maintenance therapy after allogeneic haematopoietic stem cell transplantation in patients with acute myeloid leukaemia (AML). Who is it for: It is for patients aged 12 years or older with AML subtypes known to be sensitive to menin inhibition, including those with NPM1 mutations or KMT2A rearrangements, who will undergo an allogeneic haematopoietic stem cell transplantation. Study details: This is a double-blind, randomised Phase II trial comparing oral Enzomenib (up to 200 mg) with placebo for up to 24 months post-transplant. The first 20 participants will enter a safety run-in after atleast 2 cycles of Enzomenib treatment, before expanding to 170 patients across UK, Australian, and New Zealand centres. A target population of 53 will be recruited from the Australian and New Zealand centres. What is hoped from it: The study aims to determine whether Enzomenib can improve relapse-free survival compared to placebo, reduce the risk of disease recurrence, and provide a well-tolerated maintenance option after allogeneic haematopoietic stem cell transplantation for high-risk AML patients.

The purpose of this study is to improve survivorship of cancer patients in relation with cardiovascular condition. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with cancer and have cardiovascular risks. Study details Participants will be randomised 1:1 to either intervention or usual care(control group). All participants will also be asked to complete an interview and assessments at baseline and be followed up for 12 months and optional 24 months which includes vital signs, blood tests, ECG, echocardiongram,and questonnaires. If the test results are available, we'll collect data through medical records, however it these are not available, participants are asked to do the tests. Intervention group will be seen by cardio-oncology team at least 3 monthly with additional care. It is hoped that this study will help improve survivorship in patient with cancer while minimising interruption of cancer therapy and cardiovascular risks and managing cardiotoxicity.

The purpose of this study is to evaluate the effectiveness of using VR Nature (nature scenes shown through virtual reality) to reduce pain and symptoms of psychological distress for people with SCI in inpatient contexts. We are predicting that after two-weeks of VR Nature, people will reduce in their pain, and also report a decrease in their symptoms of depression, anxiety, and stress.

This study aims to find out whether following a healthy eating plan that includes anti-inflammatory foods can help improve pain, quality of life, and health in people with osteoarthritis. Participants will be randomly assigned to one of two groups: one group will follow the Australian Dietary Guidelines (Healthy Diet A), and the other group will follow the same guidelines plus additional anti-inflammatory foods (Healthy Diet B). Both diets will be supported by regular sessions with dietitians over 12 weeks. The study will measure changes in pain, physical function, quality of life, mood, sleep, and blood markers of inflammation. We hypothesise that the group following the anti-inflammatory diet will experience greater improvements in quality of life, pain, and inflammation compared to those following the standard healthy eating plan.

Period pain and symptoms impact many facets of young people’s lives. Early intervention in young people is critical to reducing the lifelong personal and societal impacts of period pain and symptoms and potential secondary causes such as endometriosis. However, problematically, young people do not know how to determine the normality of their menstrual pain, and the severity of impact that requires self management and help-seeking. Timely detection and early intervention for problematic period pain and symptoms may improve the health and wellbeing of young people. The purpose of this research is to conduct a randomised, controlled, three arm pilot trial to investigate the feasibility and acceptability of two web-based menstrual impact screening interventions compared with a control, in young people (14-25 years) with period pain and symptoms.

Endoscopic Lung volume Reduction (ELVR) is an established treatment for severe Chronic Obstructive Pulmonary Disease (COPD). Endobronchial valves are an accepted management option for achieving lung volume reduction, but are not suitable for every patient. Over 50% of patients are unable to have one way valves because of anatomical deficits ('fissures') in the lobes of the lung. Patients with >95% fissure completeness are eligible for valves; patients with 80-95% fissure completeness are further assessed for possible valve options but currently in Australia, there are no therapeutic options for patients with fissure completeness < 80%. This study seeks to expand the ELVR technique to patients not suitable for ELVR with standard approaches (such as endobronchial valves) by using segmental delivery of a polymer foam sealant called AeriSeal ® in patients with a fissure completeness < 80% for the targeted lobe. Polymer sealant allows lung volume reduction in these COPD patients who have no other alternatives.

This pragmatic pilot feasibility study evaluated the real-world implementation of PainPLaN, a co-designed pain science education resource, by physiotherapists in private practice settings with patients experiencing chronic or recurrent pain. The overarching aim of this study was to assess the feasibility, use, acceptability, satisfaction, and feedback on potential improvements for the resource, as reported by both physiotherapists and patients.

This study aims to find out whether stopping inhaled corticosteroid (ICS) puffers for a longer period before a breathing test makes the test more accurate in diagnosing asthma. Many people use ICS puffers regularly to control asthma symptoms, but these medicines can temporarily reduce airway sensitivity and may cause false-negative results when testing for asthma. In this study, adults referred for a bronchoprovocation (breathing challenge) test will be randomly assigned to withhold their ICS medication for either 72 hours (standard practice) or seven days, with some extending to three weeks if needed. Researchers will then compare how often the test correctly detects asthma between the groups. The study’s main hypothesis is that longer ICS withholding periods will improve the sensitivity and accuracy of asthma testing. Findings from this research may help refine national testing guidelines and improve how asthma is diagnosed and managed in clinical practice.

This is a FIH randomized, double-blind, placebo-controlled study of the safety, tolerability, PK, and PD following single and multiple intravenously or subcutaneous doses of CLD-423 in healthy adult participants

This study is investigating whether a mobile app called Gro Health can help people with type 2 diabetes improve their health. The app provides education and support to help users make changes to their diet, physical activity, sleep, and mental wellbeing. Adults with type 2 diabetes will be randomly assigned to receive access to the Gro Health app for 6 months in addition to their usual care, or to continue with usual care alone. After 6 months, the control group will be offered access to the app. The main outcome is to see whether using the app improves blood glucose levels (HbA1c) over 6 months, as well as other health measures like cholesterol, weight, and blood pressure.